The transition through menopause presents unique challenges for women with epilepsy, particularly due to hormonal fluctuations that may increase seizure susceptibility. A narrative review published in Neurology Clinical Practice addresses the need for an adaptive clinical pathway to guide clinicians treating this population, as evidence on managing both conditions simultaneously remains scarce. From 2016 to 2026, over 37,000 peer-reviewed articles addressed epilepsy, yet only 12 examined its interplay with menopause.
Perimenopause Screening and Antiseizure Medication Assessment
Women with epilepsy are advised to begin menopause screening between ages 35 and 50, focusing on vasomotor symptoms like hot flashes, night sweats, and sleep disturbances, as well as genitourinary issues such as vaginal dryness and painful intercourse. However, overlapping symptoms between menopause and epilepsy can complicate diagnosis, prompting physicians to also monitor changes in sleep, mood, and cognition. Shifts in seizure frequency may signal an impending transition, as hormonal changes can exacerbate seizure control.
Smith and colleagues emphasize reviewing current antiseizure medications (ASMs) to evaluate their efficacy amid menopausal shifts. Dr. Mona Sazgar, a clinical neurology professor at UC Irvine Health, recommends patients maintain a diary to track seizure trends alongside menopausal triggers like sleep disruption.
Lamotrigine clearance slows by up to 22% in older women, necessitating potential dose modifications. Enzyme-inducing ASMs like phenobarbital or carbamazepine can alter lamotrigine metabolism, while inhibitors may extend its clearance. These drugs also affect neuroendocrine systems; for instance, enzyme-inducing ASMs increase estrogen metabolism, potentially reducing oral estrogen efficacy. Levetiracetam, by contrast, has no known neuroendocrine interactions.
Menopause Treatment Options and Bone Health
Hormone therapy, often standard for general menopause, lacks robust evidence for women with epilepsy. Estrogen may heighten seizure risk by enhancing glutamate transmission, though definitive links to exogenous hormones remain unclear. Dr. Sazgar advises avoiding hormonal treatments if possible, but if necessary, recommends transdermal estradiol combined with micronized progesterone, which bypasses hepatic metabolism and leverages progesterone’s antiseizure properties.
Read Also: Experts Redefine Obesity Treatment Success Metrics
Understanding that progesterone and its metabolite, allopregnanolone, reduce glutamate excitability and positively modulate inhibitory gamma-aminobutyric acid (GABA) transmission might be encouraging for women with epilepsy seeking a combination hormonal therapy.7,8 Nonhormonal treatments used to reduce menopause symptoms include some selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs).9 Smith et
Enzyme-inducing ASMs like phenytoin are linked to bone density loss through mechanisms affecting vitamin D metabolism and chondrocyte function. Dr. Sazgar stresses monitoring vitamin D and calcium levels, promoting weight-bearing exercise, and scheduling regular bone density scans. Nonenzyme-inducing ASMs like lamotrigine and levetiracetam carry lower osteoporosis risk, whereas gabapentin and zonisamide may still contribute.
Bone Health Mechanisms and Monitoring
Enzyme-inducing ASMs like carbamazepine and phenytoin contribute to osteoporosis through multiple pathways. Physicians should assess serum levels, recommend calcium and vitamin D supplementation, and schedule periodic bone density scans to detect early bone loss.
Postmenopause Management Framework
The adaptive clinical pathway remains consistent postmenopause, with four core steps guiding care. Second, addressing modifiable triggers like sleep disruptions, mood changes, and vasomotor symptoms helps stabilize health. Finally, ongoing osteoporosis risk assessment guides preventive strategies.